Anal Squamous Cell Carcinoma — Trials

Anal Squamous Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

51 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 24
Recruiting: 13
Ph III recruiting: 1
Growth YoY: —
Industry share: 21%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05582031	Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers(REFIT-MSS)	withdrawn	Phase 2	0	Translational Research in OncologyOTHER	0	Jun 7, 2023	clinicaltrials
NCT04499352	A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer	withdrawn	Phase 2	0	Boehringer IngelheimINDUSTRY	1	Nov 15, 2021